文献速递消化系统肿瘤

转移性结直肠癌一线伊立替康生存获益的性别差异:XELAVIRI III期试验亚组分析

Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110).
PubMed 文献 · Eur J Cancer · 2021-02-27

XELAVIRI研究比较序贯(A组)与初始(B组)伊立替康联合氟尿嘧啶和贝伐珠单抗治疗转移性结直肠癌,全文分析未显示TFS非劣效。本亚组分析评估性别对疗效和耐受性的影响,共纳入421例患者(男281例,女140例)。男性初始伊立替康组ORR、PFS和OS均显著优于序贯组,女性则未观察到获益,OS多因素分析反而显示不利趋势,治疗与性别交互作用显著。

要点

  • 男性初始伊立替康组ORR 58.3% vs 33.6%,PFS HR 0.54,OS HR 0.63,均显著获益。
  • 女性初始伊立替康组ORR 43.1% vs 42.7%,PFS HR 1.09,OS多因素HR 1.78(P=0.02),无获益。
  • 治疗与性别交互作用在ORR(P=0.018)、PFS(P=0.002)和OS(P=0.001)均显著。

核心结论

  • 性别与初始伊立替康联合氟尿嘧啶和贝伐珠单抗的疗效存在交互作用,男性显著获益而女性未观察到获益。

研究设计与样本

  • XELAVIRI III期试验(NCT01249638)的亚组分析,比较序贯(A组)与初始(B组)伊立替康联合氟尿嘧啶和贝伐珠单抗。
  • 共评估421例患者,其中男性281例,女性140例,按性别和分子亚组(如RAS突变状态)分析。
  • 采用似然比检验评估治疗与性别的交互作用。

主要发现

  • 男性患者中,初始伊立替康组ORR为58.3%,序贯组为33.6%(P<0.001)。
  • 男性患者中,初始伊立替康组PFS显著更优(HR 0.54;95%CI 0.42-0.69;P<0.001),OS亦显著更优(HR 0.63;95%CI 0.47-0.85;P=0.002)。
  • 女性患者中,初始伊立替康组与序贯组ORR分别为43.1%和42.7%,PFS相似(HR 1.09;95%CI 0.76-1.55;P=0.649)。
  • 女性患者中,初始伊立替康组OS呈现不利趋势(HR 1.46;95%CI 0.95-2.24;P=0.081),多因素分析中达到显著(HR 1.78;95%CI 1.08-2.95;P=0.02)。
  • 治疗与性别交互作用在ORR(P=0.018)、PFS(P=0.002)和OS(P=0.001)均显著,治疗相关不良事件在男女间无显著差异。

临床怎么用

  • 对于男性转移性结直肠癌患者,初始伊立替康联合氟尿嘧啶和贝伐珠单抗可能带来显著生存获益。
  • 对于女性患者,该初始联合策略未显示获益,甚至OS可能存在不利影响,决策时需谨慎权衡。

局限性

  • 本分析为III期试验的亚组分析,样本量有限(女性140例),结果需前瞻性验证。
  • 全文分析未显示TFS非劣效,亚组分析的解释需结合整体研究结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: XELAVIRI compared sequential (Arm A) versus initial (Arm B) irinotecan in combination with fluoropyrimidine plus bevacizumab in patients with metastatic colorectal cancer, trial identification: NCT01249638. In the full analysis set of the study, non-inferiority of time to failure of strategy (TFS) was not shown. The present analysis was performed to evaluate the effect of gender on treatment outcome and tolerability. METHODS: The study end-points overall response rate (ORR), progression-free survival (PFS), TFS and overall survival (OS) were evaluated in female versus male patients and in molecular subgroups (i.e. RAS mutational status). Interaction of treatment and gender was tested by likelihood ratio tests. RESULTS: In total, 281 male and 140 female patients (n = 421) were evaluated. Among the male patients, the ORR was 33.6% without and 58.3% with initial irinotecan (P < 0.001). PFS (hazard ratio [HR] 0.54; 95% confidence interval [CI] 0.42-0.69; P < 0.001) and OS (HR 0.63; 95% CI 0.47-0.85; P = 0.002) were also significantly better with initial irinotecan. Among the female patients, the ORR was 42.7% in Arm A and 43.1% in Arm B, PFS was similar (HR 1.09; 95% CI 0.76-1.55; P = 0.649) without and with initial irinotecan. A strong trend for inferior outcome with regard to OS with initial irinotecan was observed (HR 1.46; 95% CI 0.95-2.24; P = 0.081) and the trend reached significance in the multivariate analysis (HR 1.78; 95% CI 1.08-2.95; P = 0.02). Formal interaction of treatment and gender was observed for ORR (P = 0.018), PFS (P = 0.002) and OS (P = 0.001). Treatment-related adverse events were not significantly different between male and female patients. CONCLUSIONS: The present analysis suggests that gender interacts with efficacy of initial irinotecan when used in combination with fluoropyrimidines and bevacizumab. Although male patients derived a significant and clinically meaningful benefit from initial combination chemotherapy, this was not observed in female patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Heinrich K, Modest DP, Ricard I, et al. Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110). Eur J Cancer. 2021. PMID: 33647548. doi:10.1016/j.ejca.2021.01.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。